Platinum antitumor compounds second-generation

Antitumor drugs cisplatin as, history, 37 175-179 platinum compounds future studies, 37 206-208 resistance to, 37 192-193 second-generation, 37 178 Antiviral agents, 36 37-38 AOR, see Aldehyde oxidoreductase Aphanothece sacrum, ferredoxins, amino acid sequence, 38 225-227 Apo-calcylin, 46 455 Apo-caldodulin, 46 449-450 Apoenzyme, 22 424 Apoferritin biosynthesis, 36 457 cystalline iron core, 36 423 Fe(III)distribution, 36 458-459 Fe(II) sequestration, 36 463-464 ferroxidase centers, 36 457-458 iron core reconstruction in shell, 36 457 mineralization, 36 25 Mdssbauer spectra, 36 459-460 optical absorbance spectra, 36 418-419 subunit conformation and quaternary structure, 36 470-471... 

Almost 40 years ago, cisplatin, a square planar coordination compound of platinum(II), was found to be an effective antitumor agent. It forms complexes with some of the nitrogen bases of DNA, producing mutations during the replication of cancer cells. Second-generation square-planar platinum(II) complexes such as carboplatin and oxaliplatin that have less severe side effects are now available. Octahedral platinum(IV) complexes such as satraplatin as well as triplatin, a tri-nuclear platinum(II) complex, are in various stages of development. A new class of ruthenium(III) anticancer complexes hold promise of targeting additional cancer types with fewer side effects. 

---